FLT3 and acute myeloid leukemia: The choice depends on the involved organ, the synchronous presence of medullary involvement of the AML, and any previous lines of treatment for the underlying disease (prior allo-HSCT); furthermore, as already discussed, the choice of therapy is contingent upon the presence of targetable abnormalities (e.g., FLT3 and IDH1/2 mutations).